Ketoconazol Actavis

Ketoconazole, the active ingredient in Ketoconazol Actavis, is an imidazole antifungal presented as a topical formulation for skin use. It treats superficial fungal infections such as dermatophytosis, seborrheic dermatitis, and pityriasis versicolor in adults and children.

GNH USA supplies Ketoconazol Actavis as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketoconazol Actavis is an imidazole antifungal that acts on superficial fungal infections of the skin.

Dermatophytosis (tinea corporis, tinea cruris, tinea pedis): Reduces fungal growth and promotes healing of skin lesions. Seborrheic dermatitis: Controls Malassezia yeast overgrowth, decreasing scaling and erythema. Pityriasis versicolor: Inhibits the causative yeast, leading to normalization of skin pigmentation.

Ketoconazol Actavis may cause local skin reactions when applied.

Common Side Effects: - Burning or stinging sensation at the application site - Itching or pruritus - Dryness or flaking of the skin - Redness or erythema - Mild irritation or contact dermatitis - Peeling of treated skin

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis, angioedema) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Systemic absorption leading to hepatic dysfunction - Adrenal suppression with prolonged use - Photosensitivity reactions - Secondary bacterial infection of the treated area

Before using Ketoconazol Actavis, consider the following precautions.

Avoid use on broken or inflamed skin: Apply only to intact skin surfaces. Do not combine with other topical antifungals: May increase irritation risk. Use as directed: Follow prescriber instructions for frequency and duration. Monitor for allergic reactions: Discontinue if severe rash or swelling occurs. Limit prolonged use: Extended therapy should be under medical supervision. Store at room temperature: Keep in original container, protect from moisture and light.

Ketoconazol Actavis may interact with other substances; consider these categories.

Major Interactions (Avoid): - Concurrent systemic use of strong CYP3A4 inhibitors: May increase systemic ketoconazole levels if absorbed. - Use with other topical azoles on the same area: Can heighten local irritation.

Moderate Interactions (Monitor Closely): - Co‑application with corticosteroid creams: May mask signs of infection. - Use with occlusive dressings: Enhances absorption, increasing risk of systemic effects. - Interaction with photosensitizing agents: May worsen photosensitivity reactions.